FAERS pharmacovigilance data for semaglutide — anyone have experience?

BariatricNurseD said:

Steady state is the thing most people miss.

Thank you for spelling out the reasoning rather than just the conclusion.

Clinical perspective, offered as context rather than as advice.

bri_stats said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

PharmD_Rodriguez said:

The mechanism that matters here is not stomach emptying, it is central.

I read this differently from PharmD_Rodriguez, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

I would rather be corrected than agreed with, if it comes to it.

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Moderator note: a couple of off-topic posts removed. Tagging this one for the weekly digest.